Quantum BioPharma Ltd. (NASDAQ: QNTM) has filed a supplement to its September 28, 2026, management information circular ahead of its annual general and special meeting of shareholders scheduled for November 10, 2026. The supplement corrects and restates the proposed special resolution authorizing a consolidation of the company’s Class A multiple voting shares and Class B subordinate voting shares. This clarification is important because it provides shareholders with precise terms for the share consolidation, reducing uncertainty and potential disputes ahead of the vote.
Under the clarified terms, fractional shares equal to or less than one-half will be rounded down to the nearest whole share, while fractions greater than one-half will be rounded up. The company also clarified that it will implement measures to cap the aggregate voting power of multiple voting shareholders at 70% if cancellations of Class B subordinate voting shares would otherwise cause that threshold to be exceeded. These details are critical for shareholders to understand how their holdings and voting influence may be affected by the consolidation. Previously submitted proxies will remain valid unless revoked or changed, and shareholders are encouraged to review the supplemental materials before the meeting. For full details, see the full press release.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum focuses on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company also invented UNBUZZD™ and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake and royalty rights. The latest news and updates relating to QNTM are available in the company’s newsroom.
The announcement was distributed through MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio at IBN, which delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries. IBN also provides editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MissionIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.
The clarification of share consolidation terms matters because it ensures transparency and fairness in the voting process, which is essential for maintaining investor confidence. For Quantum BioPharma, a clear consolidation structure may facilitate the company’s strategic objectives, including potential future financing or listing requirements. Shareholders are advised to review the supplemental materials carefully before the November 10 meeting to make informed decisions. As the company continues to advance its biotech portfolio, clear governance measures like these are fundamental to sustaining investor trust and supporting long-term growth.
